Shigeo Hayashi

Specification of the embryonic limb primordium by graded activity of Decapentaplegic

Satoshi Goto, Shigeo Hayashi · Development · 1997 · 104 citations

Life Sciences, Developmental Biology, Genetics +17

Novel Non-Peptide Nociceptin/Orphanin FQ Receptor Agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3<i>R</i>)-3-piperidinyl]-1<i>H</i>-benzimidazole: Design, Synthesis, and Structure−Activity Relationship of Oral Receptor Occupancy in the Brain for Orally Potent Antianxiety Drug

Shigeo Hayashi, Akiko Hirao, Aki Imai et al. · Journal of Medicinal Chemistry · 2009 · 46 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure–activity relationship for anti-inflammatory drug

Shigeo Hayashi, Naomi Ueno, Akio Murase et al. · European Journal of Medicinal Chemistry · 2012 · 41 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Pharmacological Characterization of the Newly Synthesized Nociceptin/Orphanin FQ–Receptor Agonist 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an Anxiolytic Agent

Akiko Hirao, Aki Imai, Yutaka Sugie et al. · Journal of Pharmacological Sciences · 2008 · 36 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: Design, synthesis, and structure–activity relationship

Shigeo Hayashi, Yoko Sumi, Naomi Ueno et al. · Biochemical Pharmacology · 2011 · 25 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16